Zacks Investment Research downgraded shares of IRONWOOD PHARMA (IRWD) from OUTPERFORM to NEUTRAL on January 16, 2013, with a target price of $16.10.
Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company that discovers, develops, and intends to commercialize innovative human medicines. The Company's first in class compound, Linaclotide, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation and chronic constipation. The Company also focuses on one Phase 1 pain drug candidate and multiple preclinical programs, as well as on building a specialty biochemicals business based on a proprietary strain-development platform. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is headquartered in Cambridge, Massachusetts.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on IRONWOOD PHARMA (IRWD),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment